AegirBio has received formal approval from the Notified Body on its request to prolong the shelf life of its Covid-19 antigen test. The approval is based on real-time stability data showing that the product can be stored for 24 months with the same performance. This means that the current stock of a little over 1 million tests now has a shelf life until summer 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4965 SEK | -5.25% | -17.25% | -57.56% |
06-04 | Sweden's AegirBio to Change Name to MagnOral | MT |
05-17 | AegirBio AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-57.56% | 1.8M | |
+8.46% | 220B | |
+14.38% | 194B | |
+26.90% | 149B | |
+33.90% | 113B | |
+4.45% | 65.75B | |
+15.11% | 52.43B | |
+1.93% | 50.47B | |
-4.22% | 38.54B | |
-1.75% | 34.12B |
- Stock Market
- Equities
- AEGIR Stock
- News AegirBio AB
- AegirBio Receives Approval from the Notified Body to Prolong the Shelf Life of Its Covid-19 Antigen Test